What term is used to identify when a cell is temporarily deprived of blood supply

Calcium channel blockers (CCBs) are a class of medications that block the influx of calcium ions into cardiac and smooth muscle cells, leading to relaxation of these muscles and dilation of blood vessels.

In the heart, CCBs primarily affect the L-type calcium channels in the cardiac myocytes, which are responsible for the influx of calcium ions during the plateau phase of the cardiac action potential. By blocking these channels, CCBs decrease the amount of calcium that enters the cardiac myocytes, which in turn reduces the strength of cardiac contractions (i.e. contractility).

This reduction in contractility can be beneficial in certain conditions where the heart is working too hard or experiencing insufficient blood flow, such as in hypertension, angina, or some forms of arrhythmia. By reducing the workload of the heart, CCBs can help to lower blood pressure, decrease oxygen demand, and improve blood flow to the heart.

While CCBs can also have effects on the rate and rhythm of cardiac contractions, these effects are generally less pronounced than the reduction in contractility. Some CCBs, such as verapamil and diltiazem, can slow the heart rate by blocking the L-type calcium channels in the sinoatrial (SA) and atrioventricular (AV) nodes, while others, such as nifedipine, have little effect on heart rate.

Cystic fibrosis is a genetic disorder caused by mutations in the CFTR gene, which is inherited in an autosomal recessive manner. This means that a child must inherit two copies of the mutated gene (one from each parent) to develop the disorder. If only one parent carries a copy of the mutated gene, their children will not develop cystic fibrosis but may be carriers of the gene.